Home › Funds › Enavate Sciences GP, LLC › SION
Enavate Sciences GP, LLC position in SION
SIONNA THERAPEUTICS INC · Health Care
Enavate Sciences GP, LLC reported holding 2,478,030 shares of SION (SIONNA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$109.0M, representing 31.56% of its reported portfolio and ranking #1 among its reported holdings. Enavate Sciences GP, LLC has disclosed SION holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Enavate Sciences GP, LLC's SION position evolved
Enavate Sciences GP, LLC first disclosed a stake in SION in Q1 2025 at 2,478,030 shares (US$25.9M). The position peaked in Q2 2026 at 2,478,030 shares, worth US$109.0M. Across 6 filings, Enavate Sciences GP, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,478,030 shares valued at US$109.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 2.48M | $25.92M | New |
| Q2 2025 | 2.48M | $42.99M | Hold |
| Q3 2025 | 2.48M | $72.88M | Hold |
| Q4 2025 | 2.48M | $101.95M | Hold |
| Q1 2026 | 2.48M | $99.34M | Hold |
| Q2 2026 | 2.48M | $109.01M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SION and 13F data
SION (SIONNA THERAPEUTICS INC) is a Health Care company. 86 other funds we track also report a position in SION — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$435.7M), TPG GP A, LLC (US$285.7M), Atlas Venture Life Science Advisors, LLC (US$131.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SION
- RA CAPITAL MANAGEMENT, L.P. 9.91M sh · $435.72M · Q2 2026
- TPG GP A, LLC 6.49M sh · $285.71M · Q2 2026
- Atlas Venture Life Science Advisors, LLC 3.00M sh · $131.78M · Q2 2026
- ORBIMED ADVISORS LLC 2.56M sh · $112.43M · Q2 2026
- PERCEPTIVE ADVISORS LLC 905.00K sh · $39.81M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 680.92K sh · $29.95M · Q2 2026
- Siren, L.L.C. 610.51K sh · $26.86M · Q2 2026
- Casdin Capital 400.00K sh · $17.60M · Q2 2026
- Kalehua Capital Management LLC 197.07K sh · $8.67M · Q2 2026
- Sofinnova Investments, Inc. 144.43K sh · $6.35M · Q2 2026
- GordonMD Global Investments LP 136.00K sh · $5.98M · Q2 2026
- Sio Capital Management, LLC 127.81K sh · $5.62M · Q2 2026
More on Enavate Sciences GP, LLC
FAQ
How long has Enavate Sciences GP, LLC held SION?
Enavate Sciences GP, LLC has disclosed SION holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is Enavate Sciences GP, LLC's current position in SION?
As of Q2 2026, Enavate Sciences GP, LLC holds 2.48M shares of SION (SIONNA THERAPEUTICS INC), valued at $109.01M, representing 31.56% of its reported portfolio and ranking #1.
Has Enavate Sciences GP, LLC been buying or selling SION?
In the latest 13F filing (Q2 2026), Enavate Sciences GP, LLC held unchanged its position in SION. The position peaked in Q2 2026 at 2.48M shares.
Which other funds hold SION?
Other major institutional holders of SION include RA CAPITAL MANAGEMENT, L.P., TPG GP A, LLC, Atlas Venture Life Science Advisors, LLC, among 86 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.